Nuvalent Return On Tangible Equity 2021-2025 | NUVL

Nuvalent return on tangible equity for the quarter ending March 31, 2025 was -31.36.

  • Nuvalent average return on tangible equity for 2024 was -28.33, a 9.81% increase from 2023.
  • Nuvalent average return on tangible equity for 2023 was -25.8, a 1.94% increase from 2022.
  • Nuvalent average return on tangible equity for 2022 was -25.31, a 14.87% increase from 2021.

Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.

Nuvalent Return On Tangible Equity 2021-2025 | NUVL

  • Nuvalent average return on tangible equity for 2024 was -28.33, a 9.81% increase from 2023.
  • Nuvalent average return on tangible equity for 2023 was -25.8, a 1.94% increase from 2022.
  • Nuvalent average return on tangible equity for 2022 was -25.31, a 14.87% increase from 2021.

Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$222.7B
Amgen (AMGN)$161.5B
Gilead Sciences (GILD)$142.5B
Vertex Pharmaceuticals (VRTX)$123.1B
Bristol Myers Squibb (BMY)$98.7B
GSK (GSK)$81B
CSL (CSLLY)$78.2B
Regeneron Pharmaceuticals (REGN)$60.4B
Alnylam Pharmaceuticals (ALNY)$42.1B
Argenex SE (ARGX)$34.4B
BioNTech SE (BNTX)$27.4B
Royalty Pharma (RPRX)$20.3B
Biogen (BIIB)$19.8B
Insmed (INSM)$18.3B
Illumina (ILMN)$15.8B
Genmab (GNMSF)$14B
Genmab (GMAB)$14B
Incyte (INCY)$13.6B
Moderna (MRNA)$13.3B
Exelixis (EXEL)$12.3B
BioMarin Pharmaceutical (BMRN)$11.3B
QIAGEN (QGEN)$10.8B
Ascendis Pharma (ASND)$10.8B
Swedish Orphan Biovitrum (BIOVF)$10.4B
Exact Sciences (EXAS)$10.1B
Verona Pharma American Depositary Share (VRNA)$8.9B
Bio-Techne Corp (TECH)$8.5B
Blueprint Medicines (BPMC)$8.4B
Regencell Bioscience Holdings (RGC)$8.2B
Roivant Sciences (ROIV)$7.9B